Metabolomics-Based Elucidation of Therapeutic Mechanism of Luteolin Towards Autism in Children and Relevant Drug-Drug Interaction Risk

被引：0
|
作者：
Sun, Xingzhen [1 ]
Li, Chaoyang [1 ]
Wang, Xiang [1 ]
Zhang, Rongrong [1 ]
Hong, Ze [1 ]
机构：
[1] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Gen Pediat, Huaian 223300, Jiangsu, Peoples R China
来源：
LATIN AMERICAN JOURNAL OF PHARMACY | 2015年 / 34卷 / 03期
关键词：
autism; drug safety; lutrolin; metabolomics; SPECTRUM DISORDERS; FORMULATION;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Limited understanding for pathogenetic autism spectrum disorders results in the limited drugs for these diseases. In the present study, metabolomics-based analysis method was employed to compare healthy volunteers (n = 10), autism children (n = 10), and luteolin-treated autism children (n = 10). The results showed that autism children exhibited higher long-chain fatty acid-carnitine conjugates than healthy volunteers, indicating the inhibition of fatty acids oxidative process in autism children. The treatment with luteolin significantly decreased the level of long-chain fatty acid-carnitine conjugates. The drug-drug interaction risk between luteolin and zidovudine was furtherly determined, and the results showed that luteolin did not affect the metabolism of these two drugs. In conclusion, metabolomics-based analysis of luteolin-treated autism patients showed that luteolin can reverse autism-induced inhibition of fatty acids metabolism. Additionally, this drug is relatively safe because of none of drug-drug interaction.
引用
收藏
页码：590 / 592
页数：3
相关论文
共 50 条
  • [21] Utilizing Drug-Drug Interaction Prediction Tools during Drug Development: Enhanced Decision Making Based on Clinical Risk
    Shardlow, Carole E.
    Generaux, Grant T.
    MacLauchlin, Christopher C.
    Pons, Nicoletta
    Skordos, Konstantine W.
    Bloomer, Jackie C.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (11) : 2076 - 2084
  • [22] Low risk of drug-drug interactions for Ruzasvir based upon in vitro metabolism and transporter interaction studies
    Vo, Alex
    Yabut, Jocelyn
    Hafey, Michael
    Wan, Hui
    Agrawal, Nancy
    Sommadossi, Jean-Pierre
    JOURNAL OF HEPATOLOGY, 2024, 80 : S753 - S753
  • [23] Model-based assessments of CYP3A-mediated drug-drug interaction risk of milademetan
    Hong, Ying
    Ishizuka, Tomoko
    Watanabe, Akiko
    Tachibana, Masaya
    Lee, Mark
    Ishizuka, Hitoshi
    LaCreta, Frank
    Abutarif, Malaz
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06): : 2220 - 2230
  • [24] Multi-view Feature Fusion Based on Self-attention Mechanism for Drug-drug Interaction Prediction
    Han, Hui
    Zhang, Weiyu
    Sun, Xu
    Lu, Wenpeng
    2023 INTERNATIONAL JOINT CONFERENCE ON NEURAL NETWORKS, IJCNN, 2023,
  • [25] Multisource Attention-Mechanism-Based Encoder-Decoder Model for Predicting Drug-Drug Interaction Events
    Pan, Deng
    Quan, Lijun
    Jin, Zhi
    Chen, Taoning
    Wang, Xuejiao
    Xie, Jingxin
    Wu, Tingfang
    Lyu, Qiang
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2022, 62 (23) : 6258 - 6270
  • [26] In Vivo Evaluation of Drug-Drug Interaction via Mechanism-Based Inhibition by Macrolide Antibiotics in Cynomolgus Monkeys
    Ogasawara, Akihito
    Negishi, Isao
    Kozakai, Kazumasa
    Kume, Toshiyuki
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (11) : 2127 - 2136
  • [27] Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration Between 2013 and 2016
    Yu, Jingjing
    Zhou, Zhu
    Tay-Sontheimer, Jessica
    Levy, Rene H.
    Ragueneau-Majlessi, Isabelle
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (06) : 835 - 845
  • [28] Potential drug-drug interaction prevalence and risk factors associated with QT interval prolonging psychotropic use in children and adolescents
    Das, Biswadeep
    Rawat, Vikram Singh
    Ramasubbu, Saravana Kumar
    Agnihotri, Akash
    Kumar, Barun
    PROGRESS IN PEDIATRIC CARDIOLOGY, 2022, 64
  • [29] Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models
    Yamada, Makiko
    Ishizuka, Tomoko
    Inoue, Shin-ichi
    Rozehnal, Veronika
    Fischer, Thomas
    Sugiyama, Daisuke
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (09) : 769 - 777
  • [30] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE DRUG-DRUG INTERACTION (DDI) RISK OF ALECTINIB.
    Cleary, Y.
    Gertz, M.
    Morcos, P. N.
    Youdim, K.
    Fowler, S.
    Yu, L.
    Sekiguchi, N.
    Takanashi, K.
    Kaneko, A.
    Phipps, A.
    Parrott, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S40 - S40
12345